(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression
- PMID: 32088360
- DOI: 10.1016/j.pbb.2020.172876
(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression
Abstract
Clinical and preclinical studies have shown that the N-methyl-d-aspartate receptor antagonist ketamine exerts rapid and long-lasting antidepressant effects. Although ketamine metabolites might also have potential antidepressant properties, controversial results have been reported for (2R,6R)-hydroxynorketamine ((2R,6R)-HNK) in particular, and there is little information regarding the effects of other ketamine metabolites. Here we aimed to compare the effects of (R)-norketamine ((R)-NK), (S)-NK, (2R,6R)-HNK, and (2S,6S)-HNK in a mouse model of depression induced by chronic corticosterone (CORT) injection. None of the ketamine metabolites at doses up to 20 mg/kg showed antidepressant-like activity in naïve male C57BL6/J mice. Chronic CORT treatment increased immobility in the forced swim test and caused anhedonic-like behaviors in the female encounter test. A single administration of (S)-NK and (2S,6S)-HNK dose-dependently reduced the enhanced immobility at 30 min after injection in chronic CORT-treated mice, while (R)-NK or (2R,6R)-HNK did not. Additionally, (S)-NK and (2S,6S)-HNK, but not (R)-NK or (2R,6R)-HNK, improved chronic CORT-induced anhedonia at 24 h after the injection. These results suggest that (S)-ketamine metabolites (S)-NK and (2S,6S)-HNK have potent acute and sustained antidepressant effects in rodents.
Keywords: Anti-anhedonic; Antidepressant; Behaviors; C57BL/6J mice; Depression model; Ketamine metabolites.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest Dr. Kenji Hashimoto is the inventor of filed patent applications ‘The use of (R)-ketamine in the treatment of psychiatric diseases’ and ‘(S)-norketamine and a salt thereof as pharmaceutical’ by Chiba University. Dr. Kenji Hashimoto also declares that he has received research support and consultant fees from Sumitomo Dainippon Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd. The other authors declare no conflicts of interest.
Similar articles
-
Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.Neuropsychopharmacology. 2020 Aug;45(9):1545-1556. doi: 10.1038/s41386-020-0714-z. Epub 2020 May 17. Neuropsychopharmacology. 2020. PMID: 32417852 Free PMC article.
-
Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169. doi: 10.1073/pnas.1816071116. Epub 2019 Feb 22. Proc Natl Acad Sci U S A. 2019. PMID: 30796190 Free PMC article.
-
(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13. Proc Natl Acad Sci U S A. 2019. PMID: 30867285 Free PMC article.
-
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.Biochem Pharmacol. 2020 Jul;177:113935. doi: 10.1016/j.bcp.2020.113935. Epub 2020 Mar 26. Biochem Pharmacol. 2020. PMID: 32224141 Review.
-
The antidepressant potential of (2R,6R)-hydroxynorketamine: A detailed review of pre-clinical findings.Eur J Pharmacol. 2025 Jul 15;999:177604. doi: 10.1016/j.ejphar.2025.177604. Epub 2025 Apr 8. Eur J Pharmacol. 2025. PMID: 40209847 Review.
Cited by
-
Antinociceptive and Analgesic Effects of (2R,6R)-Hydroxynorketamine.J Pharmacol Exp Ther. 2022 Sep;382(3):256-265. doi: 10.1124/jpet.122.001278. Epub 2022 Jul 2. J Pharmacol Exp Ther. 2022. PMID: 35779947 Free PMC article.
-
BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.BMC Psychiatry. 2022 Mar 15;22(1):182. doi: 10.1186/s12888-022-03838-x. BMC Psychiatry. 2022. PMID: 35291971 Free PMC article.
-
(2R,6R)-Hydroxynorketamine Treatment of Rats Exposed to Repetitive Low-Level Blast Injury.Neurotrauma Rep. 2023 Mar 30;4(1):197-217. doi: 10.1089/neur.2022.0088. eCollection 2023. Neurotrauma Rep. 2023. PMID: 37020715 Free PMC article.
-
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.Pharmacol Rev. 2021 Apr;73(2):763-791. doi: 10.1124/pharmrev.120.000149. Pharmacol Rev. 2021. PMID: 33674359 Free PMC article. Review.
-
Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines.ACS Chem Neurosci. 2022 Feb 16;13(4):510-523. doi: 10.1021/acschemneuro.1c00761. Epub 2022 Feb 3. ACS Chem Neurosci. 2022. PMID: 35113535 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical